Title: Isoquercetin to reduce viral load in COVID-19
Intervention: Quercetin (QC) and Isoquercetin (IQC) are plant bioflavonoids. They are potent antioxidant and anti-inflammatory compounds. Based on in vitro and in vivo animal and human data, it appears that QC and IQC exhibit broad spectrum antiviral activity against a number of viruses including influenza , EBOV , Zika and specific antiviral activity against SARS-CoV-2 virus.
Summary: The primary objective is to evaluate the effect of oral IQC-on the reduction of viral load. when given to patients with confirmed COVID-19 in addition to standard of care. Effects on the reduction of mortality and the rate of recovery will also be evaluated. Patients will receive treatment for 28 days and then will return 30 days following the discontinuation of treatment for a final safety visit. In addition to evaluating the effect of IQC treatment on the reduction of SARS-CoV-2 viral titers through serial RT-PCR testing, this study will look at the effect of treatment on the progression of COVID-19 disease in these patients and their rate of recovery. In addition, certain parameters which may help elucidate the mechanism of action (sLDLR, PCSK9, sACE2, D-dimers and CRP) and SARS-CoV-2 antibodies will be followed.